Axogen Inc vs Rivian Automotive, Inc. — how do they compare? Axogen Inc trades at $38.76 (market cap $2.06B), while Rivian Automotive, Inc. trades at $18.05 (market cap $25.33B). The key difference: Rivian Automotive, Inc. is far larger — about 12.3× Axogen Inc's market cap, and Axogen Inc is trading nearer its 52-week high, Rivian Automotive, Inc. nearer its low. Which is the better fit depends on your goals.
| AXGN | RIVN | |
|---|---|---|
Market Cap | $2.06B | $25.33B |
Sector | Technology | Consumer Cyclical |
52-Week High | $46.19 | $22.45 |
52-Week Low | $11.28 | $11.64 |
Enterprise Value | $1.98B | $27.07B |
Signals from Pluang's Aura AI — not financial advice
AXGN trades at $39.49, down 2.69% today, with a bearish technical signal despite recent earnings volatility. The company reported mixed quarterly results with Q3 2025 beating estimates but Q1 2026 missing expectations. Strong analyst sentiment persists with 84% buy ratings and a $47.60 consensus price target, though negative profit margins and recent technical weakness create uncertainty.
The outlook remains cautiously optimistic given strong institutional support and reimbursement progress, but investors face risks from persistent losses and competitive pressures. The stock's current position near support at $39 suggests potential for recovery if upcoming Q2 earnings meet or exceed the $0.09 EPS estimate.
Rivian Automotive (RIVN) trades at $17.31, down 0.97% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $19.22. The company has beaten EPS estimates for three consecutive quarters, though it remains unprofitable with a net income margin of -63.62%. Recent news highlights the potential of the R2 vehicle launch and a $1.74 billion stock offering to fund expansion, creating mixed investor sentiment amid growth prospects and dilution concerns.
The outlook hinges on R2 success and path to profitability, offering upside if execution improves, but high cash burn, competitive pressures, and shareholder dilution present significant risks. Analyst consensus is cautiously optimistic with 44.83% buy ratings, but the stock faces volatility around earnings and macroeconomic headwinds.
Trailing returns across standard periods
Latest headlines on both assets
Axogen is a leader in peripheral nerve regeneration and repair. It provides innovative surgical solutions and clinically proven products, like nerve grafts, to help restore function and quality of life for patients.
Read more on AXGN →Rivian Automotive, Inc. is an automotive technology company. The Company designs and manufactures vans, trucks, and sports utility vehicles, as well as offers repair and maintenance services. Rivian Automotive serves customers in North America and the United Kingdom.
Read more on RIVN →